Press

Horizons ETFs Rebalances World’s First Psychedelics ETF

Jul 7 • 1 min read

Quick Take: Horizon ETFs, has rebalanced their psychedelic-focused ETF (NEO: PSYK) Horizons ETFs Management (Canada) Inc. has completed the quarterly rebalance of the constituent holdings of Horizons Psychedelic Stock Index ETF (NEO: PSYK). PSYK is the world’s first ETF offering direct exposure to North American publicly listed securities that have significant business activities in, or significant…

Braxia Scientific Announces Participation at PSYCH Investor Summit on July 7, 2021

Jul 6 • 2 min read

Quick Take: Braxia Scientific will be participating at the PSYCH Investor Summit on July 7 Braxia Scientific Corp. (CSE: BRAX), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development. The conference will…

Seelos Therapeutics Doses First Patient in a Study of Intranasal Ketamine for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Jul 6 • 4 min read

Quick Take: Seelos Theraputics has dosed the first patient in the second part of their registrational study. The double-blind placebo-controlled study is focused on adult patients with major depression disorder at imminent risk of suicide. Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and…

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Jul 5 • 5 min read

Quick Take: Cybin has announced that their wholly-owned subsidiary, Adelia Theraputics, has achieved milestones for its pre-clinical trials. Cybin Inc. (NEO:CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved certain earn-out milestones for the period commencing January 1, 2021,…

COMPASS Pathways joins forces with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research.

Jul 5 • 3 min read

Quick Take: COMPASS Pathways has partnered with the South London Maudsley NHS Foundation Trust to advance psychedelic research and develop new mental health models for the UK. COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has signed a Memorandum of Understanding (MoU)…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435